Cancer researchPub Date : 2026-11-16DOI: 10.1158/0008-5472.can-25-5211
Zhen Xu, Christoffer Flensburg, Lorraine A. O'Reilly, Rebecca A. Bilardi, Lachlan W. Whitehead, Danielle K. Chen, Andrew Kueh, Kate D. Sutherland, Ian J. Majewski
{"title":"Hypoactive APOBEC3A Achieves High-Level Mutagenesis and Drives Squamous Cell Carcinoma.","authors":"Zhen Xu, Christoffer Flensburg, Lorraine A. O'Reilly, Rebecca A. Bilardi, Lachlan W. Whitehead, Danielle K. Chen, Andrew Kueh, Kate D. Sutherland, Ian J. Majewski","doi":"10.1158/0008-5472.can-25-5211","DOIUrl":"https://doi.org/10.1158/0008-5472.can-25-5211","url":null,"abstract":"APOBEC proteins shape the somatic mutation spectrum of many cancers by binding and editing DNA. Modeling APOBEC-induced changes in cancer has been challenging due to the toxicity of these enzymes. Here, we overcame this barrier using a mutant form of APOBEC3A with impaired deaminase activity by changing arginine 128 to alanine (A3AR128A). Overexpressing A3AR128A in murine epithelium induced squamous cell carcinoma (SCC) in the skin, head and neck region, and cervix, mirroring the human disease spectrum. Tumor formation was further accelerated by concomitant Trp53 loss. A3AR128A cancers carried frequent alterations in the NOTCH and RAS-PI3K pathways, and recurrent mutations in genes encoding histone H3 were also observed. Cross-species analysis revealed how APOBEC accessibility influences cancer driver gene selection. A catalogue of 235,790 mutations was used to refine mutational signatures linked to A3A. These results shed light on how DNA damage from A3A contributes to tumorigenesis.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"13 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149415320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-13DOI: 10.1158/0008-5472.can-26-4122
Kaizhen Wang, Xiaonan Xu, Zulaida Soto-Vargas, Shiun Chang, Nicol Mecozzi, Olga Vera, Nhan Phan, Rachel P. Kogan, Manon Chadourne, Jameela Lokhandwala, Dongliang Du, Sean J. Yoder, Jennifer M. Binning, Xiaoqing Yu, Florian A. Karreth
{"title":"RNA-Bound MYBL2 Engages the Oncogenic Transcription Factors MAFG and FRA1 to Promote Melanoma Progression","authors":"Kaizhen Wang, Xiaonan Xu, Zulaida Soto-Vargas, Shiun Chang, Nicol Mecozzi, Olga Vera, Nhan Phan, Rachel P. Kogan, Manon Chadourne, Jameela Lokhandwala, Dongliang Du, Sean J. Yoder, Jennifer M. Binning, Xiaoqing Yu, Florian A. Karreth","doi":"10.1158/0008-5472.can-26-4122","DOIUrl":"https://doi.org/10.1158/0008-5472.can-26-4122","url":null,"abstract":"Non-mutational mechanisms, including copy number alterations and transcription factor dysregulation, are critical drivers of melanoma progression. Here, we identify the transcription factor MYBL2 as a key oncogenic driver located on frequently amplified chromosome 20q. MYBL2 overexpression promoted transformation and correlated with poor survival, yet paradoxically, the transactivation function of MYBL2 was dispensable for oncogenic activity. Instead, MYBL2 acquired a non-canonical RNA-binding function enabled by the melanoma-associated RNA landscape. Through these RNA interactions, MYBL2 reshaped the chromatin landscape toward an AP-1-permissive state and promoted chromatin association of the oncogenic transcription factors MAFG and FRA1, indirectly reprogramming tumor-promoting gene networks that predict poor outcomes across multiple cancers. Importantly, a decoy RNA that disrupts the MYBL2-RNA interaction impaired MYBL2 association with MAFG and FRA1 and suppressed melanoma cell growth. These findings establish MYBL2 as an RNA-binding-dependent, 20q gain-associated driver that promotes melanoma progression through chromatin and transcriptional network remodeling.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"3 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149397320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-13DOI: 10.1158/0008-5472.can-26-1330
Svetlana Djirackor, Karolin Heinze, Ian Beddows, David Sokol, Bianca Ribeiro de Souza, Marie Adams, Martin Köbel, Michael S. Anglesio, Hui Shen
{"title":"Compartment-Resolved Profiling Identifies Shared Stromal Programs and Clarifies Molecular Subtype Origins in Ovarian Cancer","authors":"Svetlana Djirackor, Karolin Heinze, Ian Beddows, David Sokol, Bianca Ribeiro de Souza, Marie Adams, Martin Köbel, Michael S. Anglesio, Hui Shen","doi":"10.1158/0008-5472.can-26-1330","DOIUrl":"https://doi.org/10.1158/0008-5472.can-26-1330","url":null,"abstract":"Epithelial ovarian cancers (EOCs) comprise biologically distinct histotypes that arise within shared anatomical niches where tumor–stroma interactions shape tumor behavior and therapeutic response. However, most classification frameworks rely on bulk profiling that conflates epithelial and stromal contributions, limiting the understanding of crosstalk between the different compartments. Here, we performed compartment-resolved transcriptomic and epigenomic profiling of matched carcinoma and stroma across clear cell (CCOC), endometrioid (ENOC), and high-grade serous ovarian cancers (HGSC). Carcinoma profiles segregated strongly by histotype, whereas stromal profiles showed minimal histotype specificity and instead resolved into four shared groups (S1–S4). The S4 subtype, marked by a desmoplastic, myofibroblast-rich program, was enriched in omental tumors and corresponded to the HGSC C1/Mesenchymal signature. This subtype largely reflected tumor-extrinsic programs and was present beyond HGSC. Compartment-resolved analyses also refined the interpretation of other molecular carcinoma subtypes and revealed distinct carcinoma-intrinsic EMT-like programs. Together, these findings define a histotype-agnostic stromal architecture across epithelial ovarian cancers, clarify the cellular basis of canonical high-grade serous molecular subtypes, and reveal carcinoma-intrinsic EMT programs. This study underscores the value of physically separating epithelial and stromal compartments before molecular analysis and position this dataset as a multi-purpose reference resource for the EOC research community.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"18 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149398147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-12DOI: 10.1158/0008-5472.CAN-26-1941
Min Xiao, Arabella H Wan, Run Lin, Heteng Zhang, Nan You, Heng Liang, Chuwei Liu, Yuyan Zheng, Shijia Yan, Zitong Zhang, Dongyue Jiang, Meilun Chen, Huiya Cheng, Zhaolei Zou, Juan Fang, Silke Neumann, Ning Wang, Qiao-Ping Wang, Zhi Wang, Xinna Zhang, Guohui Wan
{"title":"Ketogenic Fasting Suppresses Tumor Growth and Enhances PD-1 Blockade Efficacy Through Glutamine Partitioning and Microbial Metabolite Remodeling.","authors":"Min Xiao, Arabella H Wan, Run Lin, Heteng Zhang, Nan You, Heng Liang, Chuwei Liu, Yuyan Zheng, Shijia Yan, Zitong Zhang, Dongyue Jiang, Meilun Chen, Huiya Cheng, Zhaolei Zou, Juan Fang, Silke Neumann, Ning Wang, Qiao-Ping Wang, Zhi Wang, Xinna Zhang, Guohui Wan","doi":"10.1158/0008-5472.CAN-26-1941","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-1941","url":null,"abstract":"<p><p>Many tumors remain poorly responsive to immune checkpoint blockade. The metabolic microenvironment in tumors can mediate immunosuppression by failing to sustain productive cytotoxic lymphocyte function. Here, we showed that a coordinated ketogenic-fasting (KF) regimen sensitized immune-refractory tumors to PD-1 blockade by integrating distinct metabolic and microbial effects of ketogenic diet (KD) and intermittent fasting (IF). The KF combination established a distinct immunometabolic state that could not be fully recapitulated by either KD or IF intervention alone. KF induced systemic glucose restriction while preserving intratumoral glutamine availability and selectively upregulating the glutamine transporters SLC38A1 and SLC38A2 in tumor-infiltrating CD8+ T cells and NK cells, fueling interferon-STAT1 signaling and effector activity. Single-cell transcriptomic analysis identified KF-associated cytotoxic lymphocyte states characterized by enhanced nutrient access signatures, increased effector function, and reduced terminal dysfunction. Microbiota depletion attenuated KF-mediated tumor control without abolishing intratumoral glutamine enrichment. Fecal microbiota transfer and monocolonization identified Odoribacter splanchnicus as sufficient to restore tumor control and cytotoxic T-cell activity in microbiota-depleted hosts. Mechanistically, O. splanchnicus was linked to host polyamine remodeling and indole-3-lactic acid, which supported durable CD8+ T-cell functions distinct from the glutamine-driven effector arm. KF enhanced anti-PD-1 efficacy in immune-cold tumor models, and public human datasets showed concordant associations between glutamine context, Odoribacter abundance, and immunotherapy response. Together, these findings identify a diet-responsive host-microbiota metabolic mechanism that stimulates antitumor immunity and sensitizes immune-cold tumors to immunotherapy.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination.","authors":"Shuang Wang, Jiliang Lin, Zhou-Kai Zhao, Baishen Zhang, NianDong Yi, Xin-Ke Zhang, Fei-Yang Zhang, Yongqiang Zheng, Xiao-Jiang Chen, Guo-Ming Chen, Zi-Qi Zheng, Tao Zhang, Chengcai Liang, Bai-Wei Zhao, Xiao-Xia Cai, Jin-Ling Duan, Xueyi Zheng, Chunhua Qu, Jierong Chen, Zhiwei Zhou, Ying-Bo Chen, Shuqiang Yuan, Sachiyo Nomura, Yuan-Fang Li, Run-Cong Nie, MuYan Cai","doi":"10.1158/0008-5472.CAN-25-5733","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-25-5733","url":null,"abstract":"<p><p>Lymph node metastasis (LNM) represents a pivotal event in cancer progression and a major determinant of response to immune checkpoint blockade (ICB). Elucidation of the molecular mechanisms linking metastatic dissemination to immune suppression could identify potential therapeutic targets to improve ICB efficacy. Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC). F3 was significantly upregulated in LNM-positive tumors and correlated with impaired ICB responsiveness and poor clinical outcome. Mechanistically, the intracellular domain of F3 directly bound eEF1A1 to promote STAT3 phosphorylation and induce CCL20 expression, which selectively recruited CCR6+ regulatory T cells (Tregs) to establish an immunosuppressive microenvironment. Disruption of this F3-eEF1A1-STAT3-CCL20 axis with the clinically approved compound olsalazine disodium served as a compelling preclinical proof-of-concept to potently suppress tumor growth, abrogate Treg infiltration, and restore ICB sensitivity, all without perturbing basal coagulation. These findings redefine F3 from a canonical coagulation initiator to a tumor-intrinsic immunomodulator and reveal a druggable vulnerability that uncouples its oncogenic signaling from hemostasis.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-06DOI: 10.1158/0008-5472.CAN-26-0789
Yangnan Zhang, Charis E Teh, Clare Y Slaney, Phillip K Darcy, Mark M W Chong
{"title":"Regulatory T Cell Interventions to Boost Anti-tumor Immune Responses.","authors":"Yangnan Zhang, Charis E Teh, Clare Y Slaney, Phillip K Darcy, Mark M W Chong","doi":"10.1158/0008-5472.CAN-26-0789","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-0789","url":null,"abstract":"<p><p>FOXP3-expressing regulatory T cells (Tregs) are a specialized subset of T lymphocytes that are crucial for maintaining immune homeostasis and preventing autoimmunity. However, their pervasive presence and potent immunosuppressive functions within the tumor microenvironment (TME) are a barrier to anti-tumor immunity, presenting a major challenge for cancer immunotherapy. In this review, we discuss strategies for the therapeutic modulation of Tregs. Current and emerging promising technological approaches include antibody-based approaches, small molecule inhibitors, engineered Tregs, microbiome modulation, and Treg survival manipulations. Additionally, existing and promising combinatorial therapies integrate Treg cell targeting with complementary treatment strategies. The goal of this review is to spotlight how Treg-targeted interventions can overcome immune escape and ultimately enhance immunotherapy efficacy to improve clinical outcomes in cancer patients.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-05DOI: 10.1158/0008-5472.CAN-26-1137
Felix E G Beaudry, Duhan Yendi, Danielle L A Arshinoff, Nicholas Light, Simona Perrotti, Erin Winter, Liam R Cristant, Jingxiong Xu, Julie M Wilson, Anna J Dodd, Roxana C Bucur, Eric X Chen, Elena Elimova, Rebecca K S Wong, Aruz Mesci, Ali Hosni, Anand Ghanekar, Raymond Jang, Chaya G Shwaartz, Trevor W Reichman, Carol-Anne Moulton, Enrique Sanz-Garcia, Grainne M O'Kane, Erica S Tsang, Xin Wang, Ian D McGilvray, Steven Gallinger, Trevor J Pugh, Gonzalo Sapisochin, Arndt Vogel, Jennifer J Knox, Faiyaz Notta, Robert C Grant
{"title":"Integrated Whole-Genome and Transcriptome Sequencing Reveals Divergent Evolutionary Processes Across Biliary Tract Cancer Subtypes.","authors":"Felix E G Beaudry, Duhan Yendi, Danielle L A Arshinoff, Nicholas Light, Simona Perrotti, Erin Winter, Liam R Cristant, Jingxiong Xu, Julie M Wilson, Anna J Dodd, Roxana C Bucur, Eric X Chen, Elena Elimova, Rebecca K S Wong, Aruz Mesci, Ali Hosni, Anand Ghanekar, Raymond Jang, Chaya G Shwaartz, Trevor W Reichman, Carol-Anne Moulton, Enrique Sanz-Garcia, Grainne M O'Kane, Erica S Tsang, Xin Wang, Ian D McGilvray, Steven Gallinger, Trevor J Pugh, Gonzalo Sapisochin, Arndt Vogel, Jennifer J Knox, Faiyaz Notta, Robert C Grant","doi":"10.1158/0008-5472.CAN-26-1137","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-1137","url":null,"abstract":"<p><p>Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this classification scheme may obscure shared biology and limit patient stratification. Here, we tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework. Whole-genome and transcriptome sequencing was performed on 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). The CCS segregated with anatomical location of primary tumor, and gene expression marker analyses suggested that subtypes reflect tumor cell of origin differences. The CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of the primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. This approach showed that harnessing the genomic and transcriptomic diversity of BTC provides insights into shared biology and improves stratification.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-05DOI: 10.1158/0008-5472.CAN-26-1247
Alicia Bjornberg, Aobuli Xieraili, Matthew Froid, Rowan Barker-Clarke, Jeff Maltas, Robert Vander Velde, Alexandra Kovalevich, Jamir Riffas, Virgile Caumont, Berkley E Gryder, Alexander R Anderson, David Basanta, Jacob G Scott, Virginia A Turati, Andriy Marusyk
{"title":"Selection for Targeted Therapy Resistance Indirectly Selects for Cancer Cells with Enhanced Phenotypic Plasticity and Evolvability to Orthogonal Stressors.","authors":"Alicia Bjornberg, Aobuli Xieraili, Matthew Froid, Rowan Barker-Clarke, Jeff Maltas, Robert Vander Velde, Alexandra Kovalevich, Jamir Riffas, Virgile Caumont, Berkley E Gryder, Alexander R Anderson, David Basanta, Jacob G Scott, Virginia A Turati, Andriy Marusyk","doi":"10.1158/0008-5472.CAN-26-1247","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-1247","url":null,"abstract":"<p><p>Resistance to targeted therapies is frequently associated with stem-like features and partial epithelial-to-mesenchymal transition (EMT). Understanding whether these programs directly drive resistance or instead reflect increased phenotypic plasticity is needed to guide strategies for overcoming resistance. Here, we found that resistance to ALK inhibitors (ALKi) in non-small cell lung cancer was associated with increased phenotypic plasticity, reflected in enhanced adaptability to orthogonal stressors and increased metastatic potential, without intrinsic cross-resistance in short-term assays. Computational modeling and experimental validation studies showed that plasticity was progressively enriched over multi-step resistance trajectories. Lineage tracing and clonal analyses revealed a substantial, heritable intra-cell line variability in adaptation potential. High adaptation potential was associated with increased chromatin accessibility at EMT/stemness regulators. Adaptation potential could be enhanced by inducing stemness/EMT programs and suppressed by SOX2 knockdown or epigenetic inhibition, with corresponding effects on resistance. Collectively, these findings indicate that targeted therapy indirectly selects for cells with increased phenotypic plasticity, providing a common basis for the resistance-EMT association and the substrate for multifactorial resistance and metastatic competence. Constraining plasticity could delay resistance and extend response durability.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-04DOI: 10.1158/0008-5472.CAN-26-4668
Esteban A Orellana
{"title":"Not all tRNAs are equal: how isodecoder diversity shapes cancer.","authors":"Esteban A Orellana","doi":"10.1158/0008-5472.CAN-26-4668","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-4668","url":null,"abstract":"<p><p>Several tRNAs that differ only in their body sequence decode the same codon, yet their levels and behavior vary across cell types and disease contexts. In a landmark 2014 study, a mutation in the arginine isodecoder Arg-TCT-4 was linked to neurodegeneration in mice. In 2021, increased expression of the Arg-TCT family, especially Arg-TCT-4, was unexpectedly linked to oncogenic transformation in multiple cancer models. A recent publication by Kim and colleagues reports that loss of a single tRNA isodecoder, Arg-TCT-1, drives lineage plasticity and resistance to androgen receptor pathway inhibitors in prostate cancer by reducing the translation of AGA-rich mRNAs. Together, these findings raise a broader question: what do differences in isodecoder sequence actually do? They may influence tRNA processing, charging, interactions with elongation factors and the ribosome, or the modifications tRNAs receive. This commentary places the new findings in the context of prior work and considers potential mechanisms behind the functional diversity of Arg-TCT isodecoders and their role in cancer.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer researchPub Date : 2026-11-04DOI: 10.1158/0008-5472.CAN-26-0760
Andreas D Dobbelstein, Yu-Chan Chih, Belize Acharya, Kuralay Aman, Vahid Khaki Bakhtiarvand, Alina Paul, Dennis A Agardy, Clara Tejido, Patrick Wuchter, Özlem Türeci, Ugur Sahin, Wolfgang Wick, Katharina Reinhard, Michael Platten, Lukas Bunse
{"title":"RNA Vaccination Drives Expansion and Brain-Licensing of T Cells to Enhance the Efficacy of Adoptive Cell Therapy in Glioblastoma.","authors":"Andreas D Dobbelstein, Yu-Chan Chih, Belize Acharya, Kuralay Aman, Vahid Khaki Bakhtiarvand, Alina Paul, Dennis A Agardy, Clara Tejido, Patrick Wuchter, Özlem Türeci, Ugur Sahin, Wolfgang Wick, Katharina Reinhard, Michael Platten, Lukas Bunse","doi":"10.1158/0008-5472.CAN-26-0760","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-26-0760","url":null,"abstract":"<p><p>Adoptive cell therapies using chimeric antigen receptor or T cell receptor-transgenic T cells (TCR-T) are effective in treating hematological malignancies but have limited efficacy in solid tumors, particularly brain tumors. A major challenge of adoptive T cell therapy in brain tumors is lack of access to the target antigen, which is necessary for restimulation and persistence. Here, we addressed this challenge by using an mRNA vaccine encoding the cognate antigen to induce in vivo restimulation of transferred TCR-T cells in glioma models. Delivery of mRNA encoding the immunodominant MHC class I ovalbumin epitope SIINFEKL to splenic dendritic cells initiated strong expansion of adoptively transferred ovalbumin-specific OT1 CD8+ T cells to up to 80% of all circulating CD8+ T cells. RNA vaccination markedly improved T cell infiltration and retained interferon-stimulated gene signature in the brain, suppressing glioblastoma growth. The therapeutic efficacy of this approach was further demonstrated in an experimental model for a first-in-class TCR-T cell therapy targeting an HLA-A2-restricted immunodominant epitope of the human glioblastoma stemness antigen PTPRZ1. Co-administration of human dendritic cells transfected with PTPRZ1-mRNA led to rejection of orthotopically implanted primary human gliomas endogenously expressing PTPRZ1 and HLA-A2 after adoptive transfer of PTPRZ1-TCR-T cells. In summary, these findings indicate that mRNA vaccines can boost TCR-T cell therapy against glioblastoma.</p>","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":22.6,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}